11% Reduced Exacerbations with Dual Bronchodilators
Dear Dr. Mahler:
I recently read about the results of the FLAME study on a COPD website. As I understand the post, two different bronchodilators were better for reducing flare-ups of COPD than Advair. I am 59 years old and have had COPD for four years. My doctor started me on Advair Diskus when I was diagnosed along with ProAir as needed. I have been doing pretty good, but had pneumonia this past winter. Should I ask my doctor about the two bronchodilator combination instead of taking Advair? Thanks for your advice.
Sam from Boulder, CO
The results of the FLAME study were presented at the International Conference of the American Thoracic Society in San Francisco in May 2016 and published in the New England Journal of Medicine on May 15, 2016 (doi:10:1056/NEJMoa1516385). Dr. Jadwiga Wedzicha is the first author of the study.
The FLAME study was a head-to-head comparison of: ♦ two different types of bronchodilators [indacaterol – a long-acting beta-agonist and glycopyrronium – a long-acting muscarinic antagonist] – brand name is Ultibro AND ♦ a bronchodilator [salmeterol] and an inhaled corticosteroid [fluticasone] – brand name is Advair.
3,300 patients from 43 countries participated in the study. After one year, the rate of COPD exacerbations (“flare-ups”) was 11% lower with indacaterol-glycopyrronium compared with salmeterol-fluticasone. Patients who received the two bronchodilators also had better quality of life and used albuterol as rescue medication less frequently.
Dr. Wedzicha commented that, “I think we can say that . . . a dual bronchodilator is the first choice combination that can be used in patients with COPD.”
Sam – I suggest that you discuss these findings with your doctor. You should be aware that an inhaled corticosteroid medication (such as fluticasone as found in Advair) is associated with an increased risk of pneumonia. For this reason alone, it would be reasonable to stop Advair since you had pneumonia this past winter. The reduced exacerbations (flare-ups) with indacaterol/glycopyrronium (Ultibro) is another reason to consider a dual bronchodilator inhaler. At the present, Ultibro is not available in the US.
However, Anoro Ellipta and Stiolto Respimat are dual bronchodilators available in the US and are similar to Ultibro used in the study. Neither of these medications contain a inhaled corticosteroid.
Once again, I encourage you to talk to your doctor about the results of the FLAME study and ask her/him about replacing Advair with one of the two combination bronchodilators.
Donald A. Mahler, M.D.